A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)

Trial Profile

A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Methoxsalen (Primary) ; Ciclosporin; Corticosteroids; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Mallinckrodt Inc.; Therakos
  • Most Recent Events

    • 12 Dec 2017 Results assessing safety and efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 19 Feb 2012 New source identified and integrated (Vanderbilt-Ingram Cancer Center; VICCBMT1129).
    • 28 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top